Industry P pharmaphorum
The growing use of synthetic data in modern pharma
The growing use of synthetic data in modern pharma Nicole.Raleigh Mon, 09/11/2026 - 14:02
The latest biotech and pharma news from the trade press, updated every hour and linked straight to the publisher. Follow funding, clinical, deals and more. Every story links straight to its publisher.
Industry P pharmaphorum
The growing use of synthetic data in modern pharma Nicole.Raleigh Mon, 09/11/2026 - 14:02
Research
GEN
Childhood cancers may not always need extra mutations to spread, a new review study indicates. Instead, developmental plasticity may let tumor cells shape-shift into states that help them grow, resist treatment, and ultimately metastasize. The post Childhood Cancers May Not Alway…
Industry
Labiotech
Switzerland is a booming biotech hotspot in Europe boasting many high-profile companies. Here are 10 promising Swiss biotech companies. The post Biotech in Switzerland: 10 companies to watch in 2027 appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthoriz…
Software
GEN
Computer-designed protein therapeutics move from proof-of-concept to wet-lab validation and even clinical trials as the field heats up. The post New AI Models Are Turbo-Charging Protein Design appeared first on GEN - Genetic Engineering and Biotechnology News.
Industry P Practical Fragments
From the earliest days of FBLD, fragment linking has been an aspirational goal. Snapping together two low affinity binders to get an additive or even superadditive boost in affinity is conceptually appealing but, as our poll showed, not always easy. In a new open-access J. M…
Industry P Pharmaceutical Commerce
How the midterm results stall Trump’s MFN push, and why differential pricing, compulsory licensing and transparency dominate the WHO Fair Pricing Forum.
Industry
GEN
Next-generation immunotherapy exploits diverse immune populations to address the challenges that CAR T-cell therapy faces. The post Therapeutic Immune Manipulation appeared first on GEN - Genetic Engineering and Biotechnology News.
Clinical
Clinical Trials Arena
Regulatory oversight protects patients. Operational oversight protects timelines. The strongest clinical programs integrate both for supply continuity. The post Supply continuity in clinical trials: Why certification alone is not enough appeared first on Clinical Trials Aren…
Industry
GEN
What leaders suggest are the key considerations for developing robust formulations. The post Formulation Development Roundup appeared first on GEN - Genetic Engineering and Biotechnology News.
Regulatory P pharmaphorum
MHRA grants Innovation Passports to three novel drugs Phil.Taylor Mon, 09/11/2026 - 12:55
Research S Science News
Without intervention, NSF could fully close the Social, Behavioral and Economic Sciences Directorate in a month
Industry I In the Pipeline
I’m sorry to report that Jon Clardy recently passed away due to acute myeloid leukemia. His name will be very familiar indeed to people who work in chemical biology, natural products, x-ray crystallography and several other fields, because for decades now he’s had a very large im…
Industry E EMBL
New Group Leader at EMBL Hamburg will investigate how bacteria use their metabolism to fight phages, and how phages fight back. He also plans to go further, investigating the origins of immunity and exploring the ‘dark matter’ of phage genomes to uncover new enzymes, molecules, a…
Industry P pharmaphorum
argenx agrees Unnatural takeover deal worth up to $1.15bn Phil.Taylor Mon, 09/11/2026 - 12:06
Industry P pharmaphorum
Europe’s growing vector-borne disease threat: Are we keeping pace? Nicole.Raleigh Mon, 09/11/2026 - 12:00
Clinical
MedCity News
Nkarta will present initial clinical data for its natural killer cell therapy in two disorders, myositis and systemic sclerosis, during the American College of Rheumatology annual in Orlando this week. The biotech is part of a growing group of companies developing therapies that…
Clinical A Applied Clinical Trials
In this video interview, James Cheong, senior vice president of Asia Pacific at Precision for Medicine, details how NMPA reforms, parallel reviews, and expanded reviewer capacity brought China’s startup timelines in line with the US and Europe, and could shorten them further.
Industry B BioTechniques
AMSBIO is a premier supplier of high-quality heparan sulfate (HS) monoclonal antibodies for use in brain and neurodegenerative research. In a recently published study** from Stanford University (CA, USA), these antibodies have been used to reveal a key role for endothelial glycoc…
Regulatory A Applied Clinical Trials
In today’s ACT Brief, we examine why APAC inspection findings mirror those in the US and Europe, how key risk indicators should be read together, and how FDA granted accelerated approval to a subcutaneous antibody therapy for recurrent head and neck cancer.
Research P Pharmaceutical Executive
Ignite Proteomics measures phosphorylation states to show which proteins are actively driving a tumor—guiding therapy beyond what IHC alone reveals.
Industry P pharmaphorum
Moderna to relocate its UK HQ to London's Tribeca Phil.Taylor Mon, 09/11/2026 - 10:53
Industry B BioTechniques
Original story from the University of Pennsylvania School of Engineering and Applied Science (PA, USA). A new placenta-on-a-chip model reveals how an environmental toxin affects the placenta's ability to support a developing fetus. Exposure to toxic metals like cadmium has been a…
Research
Bio.News
The price Americans pay for the Inflation Reduction Act (IRA) “pill penalty” and disincentives for follow-on research is a reduction in new cancer treatments, […] The post Cancer drug study puts numbers to the cost of IRA’s pill penalty appeared first on Bio.News.
Software S Science News
New findings demonstrate AI’s aptitude for identifying technical flaws in studies where medical decisions are on the line
Industry
Inside Precision Medicine
An experimental mRNA therapy has been able to stimulate heart muscle cells to regenerate in mice, improving the heart’s pumping ability. The post mRNA Therapy Promotes Cellular Repair After Heart Attack appeared first on Inside Precision Medicine.
Clinical
BioPharma Dive
The move from Phase II to Phase III is often treated as a clinical milestone, when it is actually a development-wide transition.
Industry
MedTech Dive
See where capital and deal activity are moving, with insights to inform stronger investment, growth and strategic decisions.
Manufacturing
PharmaVoice
Predict, optimize and act sooner with model-driven bioprocessing.
Industry
BioPharma Dive
Why early technical expertise matters when complex life sciences projects challenge convention.
Industry
BioPharma Dive
Factor incentives into expansion plans early to improve site decisions, manage commitments and free capital for what comes next.
Industry
Clinical Trials Arena
BMS has reported 56-week results from the Phase III SCOUT-HCM clinical trial assessing Camzyos in paediatric patients with symptomatic oHCM. The post BMS’s Camzyos shows continued benefit in paediatric oHCM at 56 weeks appeared first on Clinical Trials Arena.
Software
Pharmaceutical Technology
Network Bio has entered into a research collaboration with Duke University to develop AI models of human disease using biospecimens and clinical records.
Regulatory
Pharmaceutical Technology
China's NMPA has granted marketing authorisation for Bio-Thera Solutions’ BAT2506 to treat ankylosing spondylitis and rheumatoid arthritis.
Funding P pharmaphorum
Novartis' pelacarsen fail raises questions for other drugs Phil.Taylor Mon, 09/11/2026 - 09:39
Clinical
Clinical Trials Arena
OncoC4 has reported positive findings from Phase I/II trials of its investigational bispecific antibody, cesalatamig, as a monotherapy in patients with pre-treated NSCLC. The post OncoC4 announces positive Phase I/II findings for cesalatamig in NSCLC appeared first on Clinical Tr…
Industry
MHRA
Three innovative medicines with the potential to meet unmet needs in lung cancer, Huntington’s disease and Alzheimer’s disease have been given Innovation Passports, the Medicines and Healthcare products Regulatory Agency (MH…
Manufacturing P Pharmafile
AbbVie has expanded its Oxford research and development (R&D) facility with a new 12,000 sq ft site, strengthening its discovery research capabilities in immunology, neuroscience and oncology. The expansion builds on the company’s 2022 acquisition of Oxford-based biotechnolog…
Manufacturing B BioProcess International
Advances in analytical capabilities and emerging modalities are urging a reconsideration of how biosimilarity is demonstrated and regulated. Having laid the foundation for an approach based on modality-specific exposure-anchored equivalence, the author turns to practical matters,…
Clinical
Clinical Trials Arena
Experts grapple with meager participation in clinical trials from patients who feel uninformed and unsupported. The post OCT New England 2026: Tackling the Patient Enrolment Crisis appeared first on Clinical Trials Arena.